Drug intelligence / Profile preview

PSMA radioligand

Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration
Intravenous
01

Overview

PSMA radioligands are a class of targeted radiopharmaceuticals designed to bind to prostate-specific membrane antigen (PSMA), a cell-surface protein highly overexpressed in prostate cancer cells, particularly in metastatic and castration-resistant stages. These agents typically consist of a PSMA-targeting moiety (such as a small-molecule peptidomimetic, peptide, or monoclonal antibody) conjugated via a linker to a chelator holding a radioactive isotope. In theranostics, diagnostic PSMA radioligands (labeled with positron emitters like gallium-68 or fluorine-18) are used for PET imaging to select patients, while therapeutic PSMA radioligands (labeled with beta-emitters like lutetium-177 or alpha-emitters like actinium-225) deliver localized, cytotoxic radiation directly to the tumor site, causing DNA double-strand breaks and subsequent cell death. The class is led by approved therapeutics such as lutetium Lu 177 vipivotide tetraxetan (Pluvicto), which has established survival benefits across metastatic prostate cancer indications.

Other names
PSMA radioligand therapyPSMA-targeted radioligandPSMA-targeted radioligand therapyPSMA-targeted radionuclide therapyPSMA-targeted radiopharmaceuticals
02

Identity

Drug type
Radiopharmaceuticals
Modality
Antibody-Based TherapeuticsAntibody-Radionuclide Conjugates
03

Pharmacology

Route
Intravenous
04

Development

IndicationHighest phaseStatus
metastatic castration-resistant prostate cancer (mCRPC)PreclinicalActive
metastatic castration-sensitive prostate cancer (mCSPC) / metastatic hormone-sensitive prostate cancer (mHSPC)PreclinicalActive

Every indication, with countries and timelines, is in the full profile.

05

Clinical trials summary

1 trial

1 clinical trial with PSMA radioligand

By phase

  • Not stated1

By status

  • Active1

By region

  • North America1

Trial-by-trial design, status and readouts are in the full profile.

06

Regulatory

MarketStatusYear
United StatesNot approved—
European UnionNot approved—
ChinaNot approved—
JapanNot approved—

Approved indications and other markets are in the full profile.

07

Competitive landscape

Drugs on the same target
195
Drugs in the lead indication
614

Lead indication: metastatic castration-resistant prostate cancer (mCRPC)

Most advanced in the lead indication

  1. lutetium-177Approved
  2. lutetium-177 PSMAApproved
  3. lutetium Lu 177 PSMA radioligand therapyApproved
  4. 18F-PSMA-11Approved
  5. abirateroneApproved

Beyond the preview

Go deeper on PSMA radioligand.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on PSMA radioligand.

Work on PSMA radioligand? Claim this page to correct or add information. Claim this page

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call